Prophylaxis of cytomegalovirus infection in liver transplantation: A randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir

Transplantation

Volumn 64, Issue 1, 1997, Pages 66-73

  Badley, Andrew D ^a   Seaberg, Eric C ^b   Porayko, Michael K ^a   Wiesner, Russell H ^a   Keating, Michael R ^a   Wilhelm, Mark P ^a   Walker, Randall C ^a   Patel, Robin ^a   Marshall, William F ^a   Debernardi, Michael ^a   Zetterman, Rowen ^c   Steers, Jeffrey L ^a   Paya, Carlos V ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANDIDA ALBICANS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION PREVENTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACYCLOVIR; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GANCICLOVIR; GRAFT REJECTION; HUMANS; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; SURVIVAL RATE;

EID: 0030754553     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199707150-00013     Document Type: Article

References (33)

1. Patel R, Wiesner RH, Paya CV. Prophylaxis and treatment of cytomegalovirus infection after solid organ transplantation. Clin Immunother 1996; 1: 13.
2. Ljungman P, Griffiths P. Definitions of cytomegalovirus infection and disease. In: Michelson S, Plotkin SA, eds. Multidisciplinary approach to understanding cytomegalovirus disease. Amsterdam: Elsevier Science Publishers, 1993: 233.
3. Greger B, Vallbracht A, Kurth J, et al. The clinical value of CMV prophylaxis by CMV hyperimmune serum in the kidney transplant patient. Transplant Proc 1986; 18: 1387.
4. Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987; 317: 1049.
5. Fassbinder W, Ernst W, Hanke P, et al. Cytomegalovirus infections after renal transplantation: effect of prophylactic hyperimmunoglobulin. Transplant Proc 1986; 18: 1393.
6. Snydman DR, Werner BG, Dougherty NN, et al. for the Boston Center for Liver Transplantation CMVIG Study Group. Cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized, double blind, placebo-controlled trial. Ann Intern Med 1993; 10: 984.
7. Balfour HH, Chace BA, Stapleton JT, et al. A randomized placebo-controlled trial of oral ACV for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381.
8. Mollison LC, Richards MJ, Johnson PDR, et al. High-dose oral ACV reduces the incidence of cytomegalovirus infection in liver transplant recipients. J Infect Dis 1993; 168: 721.
9. Saliba F, Eyraud D, Samuel D, et al. Randomized controlled trial of ACV for the prevention of cytomegalovirus infection and disease in liver transplant recipients. Transplant Proc 1993; 25: 1444.
10. Bailey TC, Ettinger NA, Storch GA, et al. Failure of high dose oral ACV with or without globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. Am J Med 1993; 95: 273.
11. Merigan TC, Renlund DG, Keay S, et al. A controlled trial of GCV to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326: 1182.
12. Rondeau E, Bourgeon B, Peraldi MN, et al. Effect of prophylactic GCV on cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 1993; 8: 858.
13. Cohen AT, O'Grady JG, Sutherland S, Sallie R, Tan K-C, Williams R. Controlled trial of prophylactic versus therapeutic use of GCV after liver transplantation in adults. J Med Virol 1993; 40: 5.
14. Boudreaux JP, Hayes DH, Mizrahi S, Maggiore P, Blazek J, Dick D. Decreasing incidence of serious cytomegalovirus infection using GCV prophylaxis in pediatric liver transplant patients. Transplant Proc 1993; 25: 1872.
15. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomized comparison of GCV and high-dose ACV for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995; 346: 69.
16. Paya CV, Hermans PE, Wiesner RH, Smith TF, Ilstrup D, Krom RAF. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993; 18: 185.
17. Patel R, Smith TF, Espy M, et al. A prospective comparison of molecular diagnostic techniques for the early detection of cytomegalovirus in liver transplant recipients. J Infect Dis 1995; 171: 1010.
18. Breslow NE, Day NE. Statistical methods in cancer research. Vol 1. The analysis of case-control studies. Lyon, France: IARC Publications No. 32, 1980.
19. Hollander M, Wolfe DA. Nonparametric statistical methods. New York: John Wiley & Sons, 1973.
20. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.
21. Kalbfleish JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons, 1980.
22. Martin M, Manez R, Linden P, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994; 68: 779.
23. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive GCV therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled study. Ann Intern Med 1995; 123: 18.
24. Lumbreras C, Otero JR, Herrero JA, et al. GCV prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies. Antimicrob Agents Chemother 1993; 37: 2490.
25. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T. High-dose ACV compared with short-course preemptive GCV therapy to prevent cytomegalovirus disease in liver transplant recipients. Ann Intern Med 1994; 120: 375.
26. van den Berg AP, Klimpmaker IJ, Haagsma EB, et al. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis 1991; 164: 265.
27. Paya CV. Opportunistic infections: risk factor or virus-associated complication? Transplant Proc 1994; 26: 12.
28. Patel R, Portela D, Badley AD, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996; 62(7): 926.
29. Paya CV. Fungal infections in solid organ transplantation. Clin Infect Dis 1993; 16: 677.
30. Boyce NW, Hayes K, Gee D, et al. Cytomegalovirus infection complicating renal transplantation and its relationship to acute transplant glomerulopathy. Transplantation 1988; 45: 706.
31. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561.
32. Weimar W, Balk AH, Metselaar HJ, et al. On the relation between cytomegalovirus infection and rejection after heart transplantation. Transplantation 1991; 52: 162.
33. Paya CV, Wiesner RH, Hermans PE, et al. Lack of association between cytomegalovirus infection, HLA matching and the vanishing bile duct syndrome after liver transplantation. Hepatology 1992; 16: 66.